New sunscreen ingredient wins FDA approval after years of delay
New Sunscreen Ingredient Wins FDA Approval After Years of Delay
New sunscreen ingredient wins FDA approval - On Tuesday, the U.S. Food and Drug Administration (FDA) announced its approval of a groundbreaking sunscreen component, bemotrizinol, marking the first such innovation in over 25 years. This development is expected to introduce a new layer of protection for American consumers, offering a chemical solution that has been widely utilized in Europe and other international markets for decades. The decision opens the door for the ingredient to be incorporated into sunscreen formulations, addressing a longstanding gap in the U.S. market for advanced UV-blocking technologies.
What is Bemotrizinol?
Bemotrizinol, a synthetic compound, has passed the FDA’s rigorous safety and efficacy standards. The agency confirmed that it effectively shields against harmful ultraviolet (UV) radiation, specifically UVB and UVA rays, without causing significant skin irritation or being readily absorbed into the body. This makes it a viable alternative to traditional chemical sunscreens, which often rely on ingredients like oxybenzone or avobenzone. The ingredient is deemed safe for use by individuals aged six months and above, ensuring broad applicability across age groups.
The Approval Process and Market Impact
The Dutch company DSM Nutritional Products will be the first to commercialize bemotrizinol in the U.S. under the brand name Parsol Shield, with a projected launch later this year. This exclusive period, lasting 18 months, will allow DSM to secure a temporary market lead before other manufacturers can introduce products with the same ingredient. The approval of bemotrizinol is a milestone for the FDA, as it leverages a streamlined regulatory process authorized by Congress in 2020, which aims to expedite the evaluation of new nonprescription drug ingredients. This shift reflects a growing effort to modernize sunscreen standards and enhance product effectiveness.
Industry and Consumer Reactions
"The FDA’s decision represents a major step forward in advancing innovation and providing Americans with more choices in sun protection," stated Health and Human Services Secretary Robert F. Kennedy, whose department oversees the agency. The approval is seen as a catalyst for increased competition among sunscreen brands, potentially driving down prices and improving quality.
Dr. Jon LaPook, CBS News’ chief medical correspondent, highlighted bemotrizinol’s unique advantages. According to him, the ingredient’s stability under sunlight means it maintains its protective properties longer than conventional chemical blockers. This characteristic could lead to fewer reapplications, making it a practical option for daily use. David Andrews of the Environmental Working Group added that the ingredient addresses a critical need in the U.S. market: offering broad-spectrum protection without the white residue commonly associated with mineral-based sunscreens like zinc oxide or titanium dioxide.
Andrews’ organization has been a vocal advocate for updating sunscreen regulations, pushing for stricter safety protocols and the inclusion of modern ingredients. The approval of bemotrizinol aligns with their long-standing efforts, as it represents a significant departure from the outdated formulations that have dominated the American market for years. "For decades, consumers have relied on technology that is now obsolete, while other countries have progressed," Andrews noted. "This approval will help bridge that gap."
Sunscreen Standards and Regulatory Evolution
Over the past decade, the FDA has made several key updates to sunscreen regulations. In 2011, the agency moved to eliminate misleading terms such as "waterproof," requiring all products to demonstrate adequate protection against both UVA and UVB rays. This marked a turning point, as many earlier formulations only targeted UVB, leaving consumers vulnerable to UVA-related damage like skin cancer and premature aging. The 2020 legislation introduced a faster pathway for evaluating new ingredients, which was instrumental in bemotrizinol’s recent approval.
Current U.S. sunscreen regulations mandate protection against UVB rays, which are primarily responsible for sunburn, and UVA rays, which contribute to long-term skin damage. While most chemical sunscreens achieve "broad spectrum" coverage by combining multiple active ingredients, bemotrizinol stands out for its dual capability to block both types of UV radiation. This feature is particularly appealing in an era where consumers increasingly prioritize products that offer comprehensive protection without compromising aesthetics or texture.
Global Usage and Consumer Preferences
DSM’s senior regulatory manager, Carl D’Ruiz, emphasized that bemotrizinol is already a staple in the Japanese, South Korean, and European markets. Under different trade names such as BEMT or Tinosorb S, the ingredient has been widely adopted for its balance of efficacy and skin compatibility. D’Ruiz noted that travelers in these regions often opt for sunscreens containing bemotrizinol due to their non-greasy finish and reliable performance. "Consumers appreciate its seamless application and lasting protection," he said, highlighting its potential to redefine U.S. sunscreen preferences.
Dr. Mike Davis, acting director of the FDA’s drug center, praised the agency’s commitment to ensuring that over-the-counter products meet the highest safety and effectiveness benchmarks. "This approval demonstrates the FDA’s dedication to keeping pace with scientific advancements and meeting consumer demands," he added. The decision underscores the agency’s evolving approach to regulating skincare products, particularly in light of growing concerns about chemical absorption and environmental impact.
Challenges and Progress in Sunscreen Regulation
The approval of bemotrizinol followed years of bureaucratic delays that had hindered the introduction of new ingredients. Prior to the 2020 legislative changes, the FDA’s process for updating safe chemical lists was slow and complex, requiring extensive testing and documentation. Bemotrizinol’s journey from its initial 2005 filing to final approval in 2024 exemplifies the challenges faced by manufacturers seeking to innovate in the sunscreen sector. Its acceptance signals a shift toward more agile regulatory practices, which could benefit future products.
Experts argue that the FDA’s updated standards will not only enhance consumer confidence but also encourage the development of safer and more effective sunscreens. With bemotrizinol now approved, brands have an opportunity to diversify their offerings and cater to specific needs, such as water resistance or non-comedogenic formulas. This development is expected to foster a more competitive market, ultimately leading to better options for consumers. As the U.S. continues to catch up with global sunscreen advancements, the inclusion of bemotrizinol marks a promising step toward more comprehensive UV protection.